nodes	percent_of_prediction	percent_of_DWPC	metapath
Clarithromycin—CYP1A2—Carmustine—lymphatic system cancer	0.106	0.14	CbGbCtD
Clarithromycin—SLC22A7—Methotrexate—lymphatic system cancer	0.096	0.127	CbGbCtD
Clarithromycin—CYP3A5—Teniposide—lymphatic system cancer	0.0959	0.127	CbGbCtD
Clarithromycin—CYP2C19—Teniposide—lymphatic system cancer	0.0774	0.102	CbGbCtD
Clarithromycin—CYP3A7—Vincristine—lymphatic system cancer	0.0615	0.0814	CbGbCtD
Clarithromycin—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0615	0.0814	CbGbCtD
Clarithromycin—CYP3A5—Vincristine—lymphatic system cancer	0.0462	0.0611	CbGbCtD
Clarithromycin—ABCB1—Mitoxantrone—lymphatic system cancer	0.0437	0.0577	CbGbCtD
Clarithromycin—CYP3A4—Cytarabine—lymphatic system cancer	0.038	0.0502	CbGbCtD
Clarithromycin—CYP3A4—Teniposide—lymphatic system cancer	0.0374	0.0495	CbGbCtD
Clarithromycin—ABCB1—Vincristine—lymphatic system cancer	0.03	0.0397	CbGbCtD
Clarithromycin—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0262	0.0346	CbGbCtD
Clarithromycin—ABCB1—Methotrexate—lymphatic system cancer	0.0182	0.0241	CbGbCtD
Clarithromycin—CYP3A4—Vincristine—lymphatic system cancer	0.018	0.0238	CbGbCtD
Clarithromycin—Anaemia—Bleomycin—lymphatic system cancer	0.000468	0.00192	CcSEcCtD
Clarithromycin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000464	0.0019	CcSEcCtD
Clarithromycin—Asthenia—Teniposide—lymphatic system cancer	0.00046	0.00189	CcSEcCtD
Clarithromycin—Malaise—Bleomycin—lymphatic system cancer	0.000457	0.00187	CcSEcCtD
Clarithromycin—Pruritus—Teniposide—lymphatic system cancer	0.000454	0.00186	CcSEcCtD
Clarithromycin—Leukopenia—Bleomycin—lymphatic system cancer	0.000453	0.00186	CcSEcCtD
Clarithromycin—Cardiac disorder—Vincristine—lymphatic system cancer	0.00045	0.00184	CcSEcCtD
Clarithromycin—Body temperature increased—Fludarabine—lymphatic system cancer	0.000445	0.00183	CcSEcCtD
Clarithromycin—Mental disorder—Carmustine—lymphatic system cancer	0.000445	0.00182	CcSEcCtD
Clarithromycin—Vaginal infection—Methotrexate—lymphatic system cancer	0.000442	0.00181	CcSEcCtD
Clarithromycin—Malnutrition—Carmustine—lymphatic system cancer	0.000442	0.00181	CcSEcCtD
Clarithromycin—Cough—Bleomycin—lymphatic system cancer	0.000442	0.00181	CcSEcCtD
Clarithromycin—Angiopathy—Vincristine—lymphatic system cancer	0.00044	0.0018	CcSEcCtD
Clarithromycin—Diarrhoea—Teniposide—lymphatic system cancer	0.000439	0.0018	CcSEcCtD
Clarithromycin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000437	0.00179	CcSEcCtD
Clarithromycin—Myalgia—Bleomycin—lymphatic system cancer	0.000431	0.00177	CcSEcCtD
Clarithromycin—Chest pain—Bleomycin—lymphatic system cancer	0.000431	0.00177	CcSEcCtD
Clarithromycin—Back pain—Carmustine—lymphatic system cancer	0.000427	0.00175	CcSEcCtD
Clarithromycin—Discomfort—Bleomycin—lymphatic system cancer	0.000426	0.00175	CcSEcCtD
Clarithromycin—Mental disorder—Vincristine—lymphatic system cancer	0.000425	0.00174	CcSEcCtD
Clarithromycin—Chills—Mitoxantrone—lymphatic system cancer	0.000423	0.00174	CcSEcCtD
Clarithromycin—Neoplasm—Methotrexate—lymphatic system cancer	0.000423	0.00174	CcSEcCtD
Clarithromycin—Confusional state—Bleomycin—lymphatic system cancer	0.000417	0.00171	CcSEcCtD
Clarithromycin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000415	0.0017	CcSEcCtD
Clarithromycin—Tremor—Carmustine—lymphatic system cancer	0.000414	0.0017	CcSEcCtD
Clarithromycin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000413	0.00169	CcSEcCtD
Clarithromycin—Infection—Bleomycin—lymphatic system cancer	0.00041	0.00168	CcSEcCtD
Clarithromycin—Anaemia—Carmustine—lymphatic system cancer	0.000408	0.00167	CcSEcCtD
Clarithromycin—Back pain—Vincristine—lymphatic system cancer	0.000408	0.00167	CcSEcCtD
Clarithromycin—Vomiting—Teniposide—lymphatic system cancer	0.000408	0.00167	CcSEcCtD
Clarithromycin—Agitation—Carmustine—lymphatic system cancer	0.000406	0.00167	CcSEcCtD
Clarithromycin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000405	0.00166	CcSEcCtD
Clarithromycin—Asthenia—Fludarabine—lymphatic system cancer	0.000404	0.00166	CcSEcCtD
Clarithromycin—Rash—Teniposide—lymphatic system cancer	0.000404	0.00166	CcSEcCtD
Clarithromycin—Dermatitis—Teniposide—lymphatic system cancer	0.000404	0.00166	CcSEcCtD
Clarithromycin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000402	0.00165	CcSEcCtD
Clarithromycin—Headache—Teniposide—lymphatic system cancer	0.000402	0.00165	CcSEcCtD
Clarithromycin—Pruritus—Fludarabine—lymphatic system cancer	0.000399	0.00163	CcSEcCtD
Clarithromycin—Back pain—Mitoxantrone—lymphatic system cancer	0.000397	0.00163	CcSEcCtD
Clarithromycin—Leukopenia—Carmustine—lymphatic system cancer	0.000396	0.00162	CcSEcCtD
Clarithromycin—Anorexia—Bleomycin—lymphatic system cancer	0.000394	0.00161	CcSEcCtD
Clarithromycin—Anaemia—Vincristine—lymphatic system cancer	0.00039	0.0016	CcSEcCtD
Clarithromycin—Agitation—Vincristine—lymphatic system cancer	0.000388	0.00159	CcSEcCtD
Clarithromycin—Diarrhoea—Fludarabine—lymphatic system cancer	0.000386	0.00158	CcSEcCtD
Clarithromycin—Convulsion—Carmustine—lymphatic system cancer	0.000383	0.00157	CcSEcCtD
Clarithromycin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000381	0.00156	CcSEcCtD
Clarithromycin—Nausea—Teniposide—lymphatic system cancer	0.000381	0.00156	CcSEcCtD
Clarithromycin—Anaemia—Mitoxantrone—lymphatic system cancer	0.00038	0.00156	CcSEcCtD
Clarithromycin—Vertigo—Vincristine—lymphatic system cancer	0.000379	0.00155	CcSEcCtD
Clarithromycin—Hepatic failure—Methotrexate—lymphatic system cancer	0.000378	0.00155	CcSEcCtD
Clarithromycin—Leukopenia—Vincristine—lymphatic system cancer	0.000378	0.00155	CcSEcCtD
Clarithromycin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000376	0.00154	CcSEcCtD
Clarithromycin—Myalgia—Carmustine—lymphatic system cancer	0.000376	0.00154	CcSEcCtD
Clarithromycin—Chest pain—Carmustine—lymphatic system cancer	0.000376	0.00154	CcSEcCtD
Clarithromycin—Anxiety—Carmustine—lymphatic system cancer	0.000375	0.00154	CcSEcCtD
Clarithromycin—Paraesthesia—Bleomycin—lymphatic system cancer	0.000371	0.00152	CcSEcCtD
Clarithromycin—Malaise—Mitoxantrone—lymphatic system cancer	0.00037	0.00152	CcSEcCtD
Clarithromycin—Dyspnoea—Bleomycin—lymphatic system cancer	0.000368	0.00151	CcSEcCtD
Clarithromycin—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000368	0.00151	CcSEcCtD
Clarithromycin—Convulsion—Vincristine—lymphatic system cancer	0.000365	0.0015	CcSEcCtD
Clarithromycin—Confusional state—Carmustine—lymphatic system cancer	0.000364	0.00149	CcSEcCtD
Clarithromycin—Decreased appetite—Bleomycin—lymphatic system cancer	0.000359	0.00147	CcSEcCtD
Clarithromycin—Myalgia—Vincristine—lymphatic system cancer	0.000359	0.00147	CcSEcCtD
Clarithromycin—Visual disturbance—Methotrexate—lymphatic system cancer	0.000359	0.00147	CcSEcCtD
Clarithromycin—Cough—Mitoxantrone—lymphatic system cancer	0.000358	0.00147	CcSEcCtD
Clarithromycin—Infection—Carmustine—lymphatic system cancer	0.000358	0.00147	CcSEcCtD
Clarithromycin—Vomiting—Fludarabine—lymphatic system cancer	0.000358	0.00147	CcSEcCtD
Clarithromycin—Convulsion—Mitoxantrone—lymphatic system cancer	0.000356	0.00146	CcSEcCtD
Clarithromycin—Rash—Fludarabine—lymphatic system cancer	0.000355	0.00146	CcSEcCtD
Clarithromycin—Dermatitis—Fludarabine—lymphatic system cancer	0.000355	0.00146	CcSEcCtD
Clarithromycin—Pain—Bleomycin—lymphatic system cancer	0.000353	0.00145	CcSEcCtD
Clarithromycin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000353	0.00145	CcSEcCtD
Clarithromycin—Headache—Fludarabine—lymphatic system cancer	0.000353	0.00145	CcSEcCtD
Clarithromycin—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000351	0.00144	CcSEcCtD
Clarithromycin—Chest pain—Mitoxantrone—lymphatic system cancer	0.00035	0.00143	CcSEcCtD
Clarithromycin—Myalgia—Mitoxantrone—lymphatic system cancer	0.00035	0.00143	CcSEcCtD
Clarithromycin—Anxiety—Mitoxantrone—lymphatic system cancer	0.000349	0.00143	CcSEcCtD
Clarithromycin—Discomfort—Mitoxantrone—lymphatic system cancer	0.000346	0.00142	CcSEcCtD
Clarithromycin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000344	0.00141	CcSEcCtD
Clarithromycin—Anorexia—Carmustine—lymphatic system cancer	0.000344	0.00141	CcSEcCtD
Clarithromycin—Infection—Vincristine—lymphatic system cancer	0.000342	0.0014	CcSEcCtD
Clarithromycin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00034	0.0014	CcSEcCtD
Clarithromycin—Confusional state—Mitoxantrone—lymphatic system cancer	0.000338	0.00139	CcSEcCtD
Clarithromycin—Nervous system disorder—Vincristine—lymphatic system cancer	0.000338	0.00138	CcSEcCtD
Clarithromycin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000337	0.00138	CcSEcCtD
Clarithromycin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000335	0.00137	CcSEcCtD
Clarithromycin—Nausea—Fludarabine—lymphatic system cancer	0.000335	0.00137	CcSEcCtD
Clarithromycin—Infection—Mitoxantrone—lymphatic system cancer	0.000333	0.00137	CcSEcCtD
Clarithromycin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000333	0.00136	CcSEcCtD
Clarithromycin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000329	0.00135	CcSEcCtD
Clarithromycin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000328	0.00135	CcSEcCtD
Clarithromycin—Urticaria—Bleomycin—lymphatic system cancer	0.000328	0.00135	CcSEcCtD
Clarithromycin—Anorexia—Vincristine—lymphatic system cancer	0.000328	0.00135	CcSEcCtD
Clarithromycin—Body temperature increased—Bleomycin—lymphatic system cancer	0.000327	0.00134	CcSEcCtD
Clarithromycin—Insomnia—Carmustine—lymphatic system cancer	0.000326	0.00134	CcSEcCtD
Clarithromycin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000326	0.00134	CcSEcCtD
Clarithromycin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000324	0.00133	CcSEcCtD
Clarithromycin—Paraesthesia—Carmustine—lymphatic system cancer	0.000324	0.00133	CcSEcCtD
Clarithromycin—Dyspnoea—Carmustine—lymphatic system cancer	0.000322	0.00132	CcSEcCtD
Clarithromycin—Somnolence—Carmustine—lymphatic system cancer	0.000321	0.00131	CcSEcCtD
Clarithromycin—Anorexia—Mitoxantrone—lymphatic system cancer	0.00032	0.00131	CcSEcCtD
Clarithromycin—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000314	0.00129	CcSEcCtD
Clarithromycin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000314	0.00129	CcSEcCtD
Clarithromycin—Decreased appetite—Carmustine—lymphatic system cancer	0.000313	0.00129	CcSEcCtD
Clarithromycin—Insomnia—Vincristine—lymphatic system cancer	0.000311	0.00128	CcSEcCtD
Clarithromycin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000311	0.00128	CcSEcCtD
Clarithromycin—Paraesthesia—Vincristine—lymphatic system cancer	0.000309	0.00127	CcSEcCtD
Clarithromycin—Pain—Carmustine—lymphatic system cancer	0.000308	0.00126	CcSEcCtD
Clarithromycin—Constipation—Carmustine—lymphatic system cancer	0.000308	0.00126	CcSEcCtD
Clarithromycin—Breast disorder—Methotrexate—lymphatic system cancer	0.000307	0.00126	CcSEcCtD
Clarithromycin—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000306	0.00125	CcSEcCtD
Clarithromycin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000305	0.00125	CcSEcCtD
Clarithromycin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000304	0.00125	CcSEcCtD
Clarithromycin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000301	0.00123	CcSEcCtD
Clarithromycin—Decreased appetite—Vincristine—lymphatic system cancer	0.000299	0.00123	CcSEcCtD
Clarithromycin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000299	0.00123	CcSEcCtD
Clarithromycin—Somnolence—Mitoxantrone—lymphatic system cancer	0.000298	0.00122	CcSEcCtD
Clarithromycin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000297	0.00122	CcSEcCtD
Clarithromycin—Feeling abnormal—Carmustine—lymphatic system cancer	0.000297	0.00122	CcSEcCtD
Clarithromycin—Fatigue—Vincristine—lymphatic system cancer	0.000297	0.00122	CcSEcCtD
Clarithromycin—Asthenia—Bleomycin—lymphatic system cancer	0.000296	0.00122	CcSEcCtD
Clarithromycin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000295	0.00121	CcSEcCtD
Clarithromycin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000295	0.00121	CcSEcCtD
Clarithromycin—Pain—Vincristine—lymphatic system cancer	0.000294	0.00121	CcSEcCtD
Clarithromycin—Constipation—Vincristine—lymphatic system cancer	0.000294	0.00121	CcSEcCtD
Clarithromycin—Asthma—Methotrexate—lymphatic system cancer	0.000294	0.0012	CcSEcCtD
Clarithromycin—Pruritus—Bleomycin—lymphatic system cancer	0.000292	0.0012	CcSEcCtD
Clarithromycin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000291	0.0012	CcSEcCtD
Clarithromycin—Eosinophilia—Methotrexate—lymphatic system cancer	0.000291	0.00119	CcSEcCtD
Clarithromycin—Fatigue—Mitoxantrone—lymphatic system cancer	0.000289	0.00119	CcSEcCtD
Clarithromycin—Pancreatitis—Methotrexate—lymphatic system cancer	0.000288	0.00118	CcSEcCtD
Clarithromycin—Constipation—Mitoxantrone—lymphatic system cancer	0.000287	0.00118	CcSEcCtD
Clarithromycin—Pain—Mitoxantrone—lymphatic system cancer	0.000287	0.00118	CcSEcCtD
Clarithromycin—Abdominal pain—Carmustine—lymphatic system cancer	0.000285	0.00117	CcSEcCtD
Clarithromycin—Body temperature increased—Carmustine—lymphatic system cancer	0.000285	0.00117	CcSEcCtD
Clarithromycin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000282	0.00115	CcSEcCtD
Clarithromycin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000276	0.00113	CcSEcCtD
Clarithromycin—Dysuria—Methotrexate—lymphatic system cancer	0.000275	0.00113	CcSEcCtD
Clarithromycin—Neutropenia—Methotrexate—lymphatic system cancer	0.000275	0.00113	CcSEcCtD
Clarithromycin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000274	0.00112	CcSEcCtD
Clarithromycin—Abdominal pain—Vincristine—lymphatic system cancer	0.000272	0.00112	CcSEcCtD
Clarithromycin—Body temperature increased—Vincristine—lymphatic system cancer	0.000272	0.00112	CcSEcCtD
Clarithromycin—Urticaria—Mitoxantrone—lymphatic system cancer	0.000266	0.00109	CcSEcCtD
Clarithromycin—Hypersensitivity—Carmustine—lymphatic system cancer	0.000266	0.00109	CcSEcCtD
Clarithromycin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000265	0.00109	CcSEcCtD
Clarithromycin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000265	0.00109	CcSEcCtD
Clarithromycin—Pneumonia—Methotrexate—lymphatic system cancer	0.000263	0.00108	CcSEcCtD
Clarithromycin—Vomiting—Bleomycin—lymphatic system cancer	0.000263	0.00108	CcSEcCtD
Clarithromycin—Infestation—Methotrexate—lymphatic system cancer	0.000262	0.00107	CcSEcCtD
Clarithromycin—Infestation NOS—Methotrexate—lymphatic system cancer	0.000262	0.00107	CcSEcCtD
Clarithromycin—Depression—Methotrexate—lymphatic system cancer	0.000261	0.00107	CcSEcCtD
Clarithromycin—Rash—Bleomycin—lymphatic system cancer	0.00026	0.00107	CcSEcCtD
Clarithromycin—Dermatitis—Bleomycin—lymphatic system cancer	0.00026	0.00107	CcSEcCtD
Clarithromycin—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00026	0.00106	CcSEcCtD
Clarithromycin—Asthenia—Carmustine—lymphatic system cancer	0.000259	0.00106	CcSEcCtD
Clarithromycin—Renal failure—Methotrexate—lymphatic system cancer	0.000257	0.00106	CcSEcCtD
Clarithromycin—Stomatitis—Methotrexate—lymphatic system cancer	0.000255	0.00105	CcSEcCtD
Clarithromycin—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000255	0.00104	CcSEcCtD
Clarithromycin—Hypersensitivity—Vincristine—lymphatic system cancer	0.000254	0.00104	CcSEcCtD
Clarithromycin—Haematuria—Methotrexate—lymphatic system cancer	0.00025	0.00102	CcSEcCtD
Clarithromycin—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000248	0.00102	CcSEcCtD
Clarithromycin—Epistaxis—Methotrexate—lymphatic system cancer	0.000247	0.00101	CcSEcCtD
Clarithromycin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000247	0.00101	CcSEcCtD
Clarithromycin—Asthenia—Vincristine—lymphatic system cancer	0.000247	0.00101	CcSEcCtD
Clarithromycin—Diarrhoea—Carmustine—lymphatic system cancer	0.000247	0.00101	CcSEcCtD
Clarithromycin—Nausea—Bleomycin—lymphatic system cancer	0.000245	0.00101	CcSEcCtD
Clarithromycin—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000244	0.001	CcSEcCtD
Clarithromycin—Asthenia—Mitoxantrone—lymphatic system cancer	0.000241	0.000986	CcSEcCtD
Clarithromycin—Dizziness—Carmustine—lymphatic system cancer	0.000238	0.000978	CcSEcCtD
Clarithromycin—Haemoglobin—Methotrexate—lymphatic system cancer	0.000236	0.000969	CcSEcCtD
Clarithromycin—Diarrhoea—Vincristine—lymphatic system cancer	0.000236	0.000966	CcSEcCtD
Clarithromycin—Haemorrhage—Methotrexate—lymphatic system cancer	0.000235	0.000964	CcSEcCtD
Clarithromycin—Hepatitis—Methotrexate—lymphatic system cancer	0.000235	0.000964	CcSEcCtD
Clarithromycin—Pharyngitis—Methotrexate—lymphatic system cancer	0.000233	0.000957	CcSEcCtD
Clarithromycin—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000232	0.000952	CcSEcCtD
Clarithromycin—Urethral disorder—Methotrexate—lymphatic system cancer	0.00023	0.000945	CcSEcCtD
Clarithromycin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000229	0.000941	CcSEcCtD
Clarithromycin—Vomiting—Carmustine—lymphatic system cancer	0.000229	0.00094	CcSEcCtD
Clarithromycin—Dizziness—Vincristine—lymphatic system cancer	0.000228	0.000933	CcSEcCtD
Clarithromycin—Rash—Carmustine—lymphatic system cancer	0.000227	0.000932	CcSEcCtD
Clarithromycin—Dermatitis—Carmustine—lymphatic system cancer	0.000227	0.000931	CcSEcCtD
Clarithromycin—Visual impairment—Methotrexate—lymphatic system cancer	0.000227	0.000929	CcSEcCtD
Clarithromycin—Headache—Carmustine—lymphatic system cancer	0.000226	0.000926	CcSEcCtD
Clarithromycin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000222	0.000912	CcSEcCtD
Clarithromycin—Eye disorder—Methotrexate—lymphatic system cancer	0.00022	0.000901	CcSEcCtD
Clarithromycin—Tinnitus—Methotrexate—lymphatic system cancer	0.000219	0.000899	CcSEcCtD
Clarithromycin—Vomiting—Vincristine—lymphatic system cancer	0.000219	0.000898	CcSEcCtD
Clarithromycin—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000218	0.000895	CcSEcCtD
Clarithromycin—Rash—Vincristine—lymphatic system cancer	0.000217	0.00089	CcSEcCtD
Clarithromycin—Dermatitis—Vincristine—lymphatic system cancer	0.000217	0.000889	CcSEcCtD
Clarithromycin—Headache—Vincristine—lymphatic system cancer	0.000216	0.000884	CcSEcCtD
Clarithromycin—Nausea—Carmustine—lymphatic system cancer	0.000214	0.000878	CcSEcCtD
Clarithromycin—Angiopathy—Methotrexate—lymphatic system cancer	0.000213	0.000875	CcSEcCtD
Clarithromycin—Vomiting—Mitoxantrone—lymphatic system cancer	0.000213	0.000874	CcSEcCtD
Clarithromycin—Immune system disorder—Methotrexate—lymphatic system cancer	0.000212	0.000871	CcSEcCtD
Clarithromycin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000212	0.000869	CcSEcCtD
Clarithromycin—Rash—Mitoxantrone—lymphatic system cancer	0.000211	0.000867	CcSEcCtD
Clarithromycin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000211	0.000866	CcSEcCtD
Clarithromycin—Chills—Methotrexate—lymphatic system cancer	0.000211	0.000865	CcSEcCtD
Clarithromycin—Headache—Mitoxantrone—lymphatic system cancer	0.00021	0.000861	CcSEcCtD
Clarithromycin—Mental disorder—Methotrexate—lymphatic system cancer	0.000206	0.000845	CcSEcCtD
Clarithromycin—Malnutrition—Methotrexate—lymphatic system cancer	0.000205	0.000839	CcSEcCtD
Clarithromycin—Nausea—Vincristine—lymphatic system cancer	0.000204	0.000838	CcSEcCtD
Clarithromycin—Dysgeusia—Methotrexate—lymphatic system cancer	0.0002	0.000822	CcSEcCtD
Clarithromycin—Nausea—Mitoxantrone—lymphatic system cancer	0.000199	0.000817	CcSEcCtD
Clarithromycin—Back pain—Methotrexate—lymphatic system cancer	0.000198	0.000812	CcSEcCtD
Clarithromycin—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00019	0.000779	CcSEcCtD
Clarithromycin—Anaemia—Methotrexate—lymphatic system cancer	0.000189	0.000776	CcSEcCtD
Clarithromycin—Malaise—Methotrexate—lymphatic system cancer	0.000185	0.000757	CcSEcCtD
Clarithromycin—Vertigo—Methotrexate—lymphatic system cancer	0.000184	0.000754	CcSEcCtD
Clarithromycin—Leukopenia—Methotrexate—lymphatic system cancer	0.000183	0.000751	CcSEcCtD
Clarithromycin—Cough—Methotrexate—lymphatic system cancer	0.000179	0.000732	CcSEcCtD
Clarithromycin—Convulsion—Methotrexate—lymphatic system cancer	0.000177	0.000727	CcSEcCtD
Clarithromycin—Myalgia—Methotrexate—lymphatic system cancer	0.000174	0.000714	CcSEcCtD
Clarithromycin—Chest pain—Methotrexate—lymphatic system cancer	0.000174	0.000714	CcSEcCtD
Clarithromycin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000173	0.00071	CcSEcCtD
Clarithromycin—Discomfort—Methotrexate—lymphatic system cancer	0.000172	0.000706	CcSEcCtD
Clarithromycin—Confusional state—Methotrexate—lymphatic system cancer	0.000168	0.000691	CcSEcCtD
Clarithromycin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000167	0.000685	CcSEcCtD
Clarithromycin—Infection—Methotrexate—lymphatic system cancer	0.000166	0.00068	CcSEcCtD
Clarithromycin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000164	0.000672	CcSEcCtD
Clarithromycin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000164	0.000671	CcSEcCtD
Clarithromycin—Skin disorder—Methotrexate—lymphatic system cancer	0.000162	0.000665	CcSEcCtD
Clarithromycin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000161	0.000662	CcSEcCtD
Clarithromycin—Anorexia—Methotrexate—lymphatic system cancer	0.000159	0.000653	CcSEcCtD
Clarithromycin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000152	0.000624	CcSEcCtD
Clarithromycin—Insomnia—Methotrexate—lymphatic system cancer	0.000151	0.000619	CcSEcCtD
Clarithromycin—Paraesthesia—Methotrexate—lymphatic system cancer	0.00015	0.000615	CcSEcCtD
Clarithromycin—Dyspnoea—Methotrexate—lymphatic system cancer	0.000149	0.000611	CcSEcCtD
Clarithromycin—Somnolence—Methotrexate—lymphatic system cancer	0.000148	0.000609	CcSEcCtD
Clarithromycin—Dyspepsia—Methotrexate—lymphatic system cancer	0.000147	0.000603	CcSEcCtD
Clarithromycin—Decreased appetite—Methotrexate—lymphatic system cancer	0.000145	0.000595	CcSEcCtD
Clarithromycin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000144	0.000591	CcSEcCtD
Clarithromycin—Fatigue—Methotrexate—lymphatic system cancer	0.000144	0.000591	CcSEcCtD
Clarithromycin—Pain—Methotrexate—lymphatic system cancer	0.000143	0.000586	CcSEcCtD
Clarithromycin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000138	0.000564	CcSEcCtD
Clarithromycin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000137	0.00056	CcSEcCtD
Clarithromycin—Urticaria—Methotrexate—lymphatic system cancer	0.000133	0.000544	CcSEcCtD
Clarithromycin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000132	0.000541	CcSEcCtD
Clarithromycin—Body temperature increased—Methotrexate—lymphatic system cancer	0.000132	0.000541	CcSEcCtD
Clarithromycin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000123	0.000505	CcSEcCtD
Clarithromycin—Asthenia—Methotrexate—lymphatic system cancer	0.00012	0.000491	CcSEcCtD
Clarithromycin—Pruritus—Methotrexate—lymphatic system cancer	0.000118	0.000485	CcSEcCtD
Clarithromycin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000114	0.000469	CcSEcCtD
Clarithromycin—Dizziness—Methotrexate—lymphatic system cancer	0.00011	0.000453	CcSEcCtD
Clarithromycin—Vomiting—Methotrexate—lymphatic system cancer	0.000106	0.000435	CcSEcCtD
Clarithromycin—Rash—Methotrexate—lymphatic system cancer	0.000105	0.000432	CcSEcCtD
Clarithromycin—Dermatitis—Methotrexate—lymphatic system cancer	0.000105	0.000431	CcSEcCtD
Clarithromycin—Headache—Methotrexate—lymphatic system cancer	0.000105	0.000429	CcSEcCtD
Clarithromycin—Nausea—Methotrexate—lymphatic system cancer	9.92e-05	0.000407	CcSEcCtD
